How do you approach a patient with metastatic urothelial carcinoma who has progressed on maintenance avelumab?  

This patient would be in the 3rd line so options include Enfortumab vedotin (based on EV-201, cohort 1, published data, and EV-301 press release) or Erdafitinib (if FGFR2 or FGFR3 activating mutation or fusion based on BLC2001 trial published data) or clinical trial. Outside the US, without access t...